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Cytotoxic T lymphocytes (CTL) are critical for control of lentiviruses, including equine infectious anemia virus (EIAV). Measurement of
equine CTL responses has relied on chromium-release assays, which do not allow accurate quantitation. Recently, the equine MHC class I
molecule 7-6, associated with the ELA-A1 haplotype, was shown to present both the Gag-GW12 and Env-RW12 EIAV CTL epitopes. In this
study, 7-6/Gag-GW12 and 7-6/Env-RW12 MHC class I/peptide tetrameric complexes were constructed and used to analyze Gag-GW12- and
Env-RW12-specific CTL responses in two EIAV-infected horses (A2164 and A2171). Gag-GW12 and Env-RW12 tetramer-positive CD8+
cells were identified in nonstimulated peripheral blood mononuclear cells as early as 14 days post-EIAV inoculation, and frequencies of
tetramer-positive cells ranged from 0.4% to 6.7% of nonstimulated peripheral blood CD8+ cells during the 127-day study period. Although
both horses terminated the initial viremic peak, only horse A2171 effectively controlled viral load. Neutralizing antibody was present during
the initial control of viral load in both horses, but the ability to maintain control correlated with Gag-GW12-specific CD8+ cells in A2171.
Despite Env-RW12 dominance, Env-RW12 escape viral variants were identified in both horses and there was no correlation between Env-
RW12-specific CD8+ cells and control of viral load. Although Gag-GW12 CTL escape did not occur, a Gag-GW12 epitope variant arose in
A2164 that was recognized less efficiently than the original epitope. These data indicate that tetramers are useful for identification and
quantitation of CTL responses in horses, and suggest that the observed control of EIAV replication and clinical disease was associated with
sustained CTL recognition of Gag-specific epitopes.
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Equine infectious anemia virus (EIAV) is a macrophage-
tropic lentivirus that causes persistent infection in horses.
Infected horses usually develop recurrent episodes of
plasma viremia and associated acute clinical disease (fever,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: rhm@vetmed.wsu.edu (R.H. Mealey).inappetence, lethargy, thrombocytopenia, and anemia) dur-
ing the first few months of infection. However, in contrast to
other lentiviral infections, including human immunodefi-
ciency virus-1 (HIV-1), most horses control EIAV repli-
cation within a year and remain persistently infected
inapparent carriers (Cheevers and McGuire, 1985; Monte-
laro et al., 1993; Sellon et al., 1994). Results of EIAV
infection in severe combined immunodeficient (SCID)
Arabian foals, as well as immune reconstitution in a SCID
foal concurrent with EIAV challenge, indicate that this05) 110 – 126
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immune responses (Perryman et al., 1988; Crawford et al.,
1996; Mealey et al., 2001). Due to robust viral-specific
immune responses that contain viral replication and clinical
disease, EIAV infection in horses is a useful model system
for the study of lentiviral immune control.
Major histocompatibility complex (MHC) class I-
restricted viral-specific CD8+ cytotoxic T lymphocytes
(CTL) are important for lentiviral immune control, including
EIAV. Direct evidence for CD8+ lymphocyte control of
simian immunodeficiency virus (SIV) in infected rhesus
monkeys is provided by in vivo depletion of CD8+
lymphocytes with monoclonal antibody (Schmitz et al.,
1999; Jin et al., 1999). Similar to HIV-1 infection, the initial
plasma viremia in acute EIAV infection is often terminated
concurrent with the appearance of CTL, but prior to the
appearance of neutralizing antibody (McGuire et al., 1990,
1994; Borrow et al., 1994; Pantaleo and Fauci, 1995). EIAV
proteins that contain CTL epitopes include Gag, Pol, Env,
Rev, and S2 (Lonning et al., 1999; McGuire et al., 2000;
Zhang et al., 1998; Mealey et al., 2003; Hammond et al.,
1997). Several optimal CTL epitopes have been mapped,
including Gag-GW12 and Env-RW12, both of which are
restricted by the ELA-A1 haplotype (Mealey et al., 2003).
The Env-RW12 epitope occurs within the V3 hypervariable
region in the envelope SU, and in one EIAV-infected ELA-
A1 horse that experienced early progressive disease, viral
variants arose that escaped Env-RW12-specific CTL recog-
nition (Mealey et al., 2003). However, since Env-RW12
occurs within the principle neutralizing domain (PND) of
EIAV SU, it is possible that neutralizing antibody was
involved in selection of the observed escape viral variants
(Mealey et al., 2003). In contrast, viral variants containing
amino acid changes within the Gag-GW12 epitope occurred
in the same horse, but did not escape CTL recognition
(Mealey et al., 2003). Interestingly, the equine MHC class I
molecule 7-6, which was derived from a horse with the
ELA-A1 haplotype, presents both the Gag-GW12 and the
Env-RW12 peptides to Gag-GW12- and Env-RW12-
specific CTL, respectively (McGuire et al., 2003). The 7-6
molecule binds the Env-RW12 peptide with higher affinity
than the Gag-GW12 peptide (McGuire et al., 2003), and
based on chromium-release assays, the Env-RW12 CTL
response is immunodominant over the Gag-GW12 response
(Mealey et al., 2003).
To date, analysis of EIAV-specific CTL responses has
relied on standard chromium-release assays, using equine
kidney cells or pokeweed mitogen-stimulated PBMC as
targets (Hammond et al., 1998; McGuire et al., 1994).
Although chromium-release assays provide important
functional information, they are technically-demanding,
labor-intensive, and utilize a radioactive isotope. Addi-
tionally, the only available method to quantitate equine
CTL has been limiting dilution analysis (Kydd et al.,
2003; McGuire et al., 1997; Mealey et al., 2001; O’Neill
et al., 1999), which requires in vitro stimulation and isknown to underestimate CTL frequency (Ogg and McMi-
chael, 1999).
The development of MHC class I/peptide tetrameric
complexes has provided a rapid method for direct identi-
fication of antigen-specific T lymphocytes in peripheral
blood (Altman et al., 1996). Tetramer staining has been
useful for analyzing SIV-specific CTL, correlating well with
cytotoxic activity, and has allowed quantitation of dominant
SIV-specific CTL responses (Egan et al., 1999). Studies
using tetramers have confirmed that the emergence of CTL
coincides with clearance of virus during SIV infection
(Kuroda et al., 1999), and that HIV-specific CTL frequency
and plasma viral load are inversely correlated (Ogg et al.,
1998), suggesting that CTL play a significant role in
controlling HIV infection. However, other work has
indicated that the inverse correlation between tetramer-
positive CD8+ T cells and viral load does not exist in HIV-
1-infected patients with low CD4+ T cell numbers,
providing evidence that tetramer-positive cells can have
impaired function, verified by measuring IFN-g production
(Kostense et al., 2001). In HIV-1-infected children, CTL
frequency as measured by IFN-g ELISPOT correlates
positively with viral load and is lower than that determined
by tetramer staining, again indicating that a significant
number of HIV-1-specific CD8+ T cells are not functional
(Buseyne et al., 2002). Similarly, intracytoplasmic IFN-g
staining has shown that total HIV-1-specific CD8+ res-
ponses correlate positively with viral load, suggesting that
frequencies of HIV-1-specific CD8+ T cells are not the sole
determinant of HIV-1 immune control (Betts et al., 2001). In
contrast, standard chromium-release assays have shown an
inverse correlation between HIV-1-specific CTL activity
and viral load in HIV-1-infected long-term survivors (Betts
et al., 1999).
Interpreting the correlations between lentiviral load and
lentivirus-specific CTL frequency, whether measured by
chromium-release assay, tetramer staining, IFN-g ELISPOT,
or intracytoplasmic IFN-g staining, remains difficult.
Positive correlations likely indicate viral replication driving
CTL expansion, or alternatively, that CTL are not effec-
tively controlling viral load. Negative correlations could
indicate effective CTL-mediated viral control, or alterna-
tively, virus-mediated immunosuppression. With respect to
the latter, transient immunosuppression associated with
febrile episodes is known to occur during EIAV infection
(Murakami et al., 1999; Newman et al., 1991).
The purpose of the present study was to determine the
relationship between CTL response and viral load during
early EIAV infection. Two tetramers, 7-6/Gag-GW12 and 7-
6/Env-RW12, were constructed to allow direct quantitation
of Gag-GW12- and Env-RW12-specific CD8+ lymphocytes
during the first 127 days of EIAV infection in two horses
(A2164 and A2171) sharing the ELA-A1 haplotype.
Chromium-release assays were also performed to confirm
functional cytotoxic activity. In addition, neutralizing anti-
body responses were measured, and plasma virus was
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arose. Results indicated that although both horses termi-
nated the initial viremic peak, viral control was transient in
A2164, whereas only horse A2171 effectively controlled
viral load and clinical disease during the 127-day observa-
tion period. An inverse correlation between Gag-GW12-
specific CD8+ cell frequency and viral load was associated
with control of plasma viremia and clinical disease in horse
A2171. There was no correlation between viral control and
Env-RW12-specific CD8+ cell frequency, despite the
immunodominance of the Env-RW12-specific response.
Although plasma viral variants that escaped Env-RW12
CTL occurred in both horses, Gag-GW12 escape did not
occur. However, a Gag-GW12 CTL epitope variant arose in
A2164 that was recognized less efficiently than the original
epitope. Interestingly, neutralizing antibody was present
during the initial control of viral load in both horses, but
neutralizing antibody activity was not associated with the
ability to maintain viral control. It was concluded that
tetramers are useful for quantitating EIAV-specific CTL
responses in horses, and that viral escape limits the
effectiveness of an immunodominant Env-RW12 CTL
response. In addition, the data suggested that Gag-specific
CTL responses are important for immune control of EIAV.Results
7-6/Env-RW12 and 7-6/Gag-GW12 tetramers identified
peptide-specific CD8+ cells in EIAV-infected horses
Stimulated PBMC from EIAV-infected ELA-A1 horse
A2140, which contain 7-6-restricted Env-RW12 and Gag-
GW12 CTL (Mealey et al., 2003), were used to confirm the
specificity of the 7-6/Env-RW12 and 7-6/Gag-GW12
tetramers. Stimulated PBMC from EIAV-infected ELA-A4
horse A2147, which do not contain Env-RW12 or Gag-
GW12 CTL, but do contain ELA-A4-restricted Gag-FK10
CTL (Mealey et al., 2003), were used as negative controls.
Prior to use, 2-fold dilutions of the stock tetramers wereFig. 1. PBMC from EIAV-infected horse A2140, stimulated for 7 days with 10 AM
serial dilutions of the 7-6/Env-RW12 tetramer: (a) 1:8; (b) 1:16; (c) 1:32; (d) nomade to determine the optimal concentration for staining.
For the 7-6/Env-RW12 tetramer, a 1:32 dilution was
considered optimal since the lowest number of CD8 cells
were labeled at this concentration (Fig. 1). Similar results
were obtained for the 7-6/Gag-GW12 tetramer (data not
shown). Both the 7-6/Env-RW12 and 7-6/Gag-GW12
tetramers labeled CD8+ cells in A2140 PBMC stimulated
with Env-RW12 (Fig. 2a) or Gag-GW12 peptides (Fig. 2c),
but not in A2147 PBMC stimulated with Gag-FK10 peptide
(Figs. 2b,d). Chromium-release CTL assays confirmed that
Env-RW12- and Gag-GW12-specific CTL were present in
the stimulated A2140 PBMC, and that Gag-FK10-specific
CTL were present in the stimulated A2147 PBMC (data not
shown). Lastly, the 7-6/Env-RW12 tetramer did not bind
Gag-GW12-stimulated A2140 PBMC (Fig. 2e), and the 7-6/
Gag-GW12 tetramer did not bind Env-RW12-stimulated
A2140 PBMC (Fig. 2f). These results indicated that
tetramer binding to equine CD8+ cells was both peptide
and MHC class I-specific.
Progressive clinical disease and high viral loads occurred
in EIAV-infected horse A2164, but not in EIAV-infected
horse A2171
During the first 127 days post-EIAV inoculation (DPI),
A2164 had six clinical disease episodes (I, DPI 5–16; II,
DPI 28–37; III, DPI 56–57; IV, DPI 71–92; V, DPI 11–
113; and VI, DPI 125–127) (Fig. 3a). All six episodes were
associated with thrombocytopenia, and fever occurred
during episodes III, V, and VI. Plasma viral RNA was
detected during each episode, with peak viral load (3.6 106
RNA copies/ml) occurring during episode III. In contrast,
A2171 had no clinical disease episodes during the same time
period (Fig. 3b). Peak plasma viral load (3.6  104 RNA
copies/ml) was 100-fold lower than that for A2164, and
occurred 12 DPI. Interestingly, plasma viral loads after DPI
50 were maintained at different levels in the two horses
(Table 1, Fig. 4). In A2171, viral load transiently increased
on DPI 71 (3.1  103 RNA copies/ml), but decreased
thereafter and was completely controlled by DPI 127. InEnv-RW12 peptide, then labeled with anti-equine CD8 and the following
tetramer.
Fig. 2. (a) PBMC from EIAV-infected horse A2140, stimulated for 7 days with Env-RW12 peptide, then labeled with anti-equine CD8 and the 7-6/Env-RW12
tetramer. (b) PBMC from EIAV-infected horse A2147, stimulated for 7 days with Gag-FK10 peptide, then labeled with anti-equine CD8 and the 7-6/Env-RW12
tetramer. (c) A2140 PBMC stimulated for 7 days with Gag-GW12 peptide, then labeled with anti-equine CD8 and the 7-6/Gag-GW12 tetramer. (d) Gag-FK10-
stimulated A2147 PBMC labeled with anti-equine CD8 and the 7-6/Gag-GW12 tetramer. (e) Gag-GW12-stimulated A2140 PBMC labeled with anti-equine
CD8 and the 7-6/Env-RW12 tetramer. (f) Env-RW12-stimulated A2140 PBMC labeled with anti-equine CD8 and the 7-6/Gag-GW12 tetramer.
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2  103 and 3.6  106 RNA copies/ml.
Env-RW12- and Gag-GW12-specific CD8+ cell frequency
in nonstimulated PBMC from EIAV-infected horses A2171
and A2164
In horse A2171, Env-RW12-specific CD8+ cells were first
detected 14 DPI, with 0.7% of nonstimulated peripheral
blood CD8+ cells binding the 7-6/Env-RW12 tetramer (Fig.
4a, Table 1). Env-RW12-specific CD8+ cell frequency
increased to 4.6% on DPI 42, and reached a peak of 6.7%
on DPI 99. In horse A2164, Env-RW12-specific CD8+ cellswere also first detected 14 DPI, with 0.2% of nonstimulated
peripheral blood CD8+ cells binding the 7-6/Env-RW12
tetramer. Env-RW12-specific CD8+ cell frequency fluctuated
in A2164, reaching a peak of 5.9% on DPI 42. With the
exception of DPI 19, 35, and 42, Env-RW12-specific CD8+
cell frequency was lower in A2164 than in A2171. Env-
RW12-specific CD8+ cell frequency was always higher in
A2171 than in A2164 after DPI 50, when viral load was more
effectively controlled in A2171.
In horse A2171, Gag-GW12-specific CD8+ cells were
first detected 14 DPI, with 0.4% of nonstimulated peripheral
blood CD8+ cells binding the 7-6/Gag-GW12 tetramer (Fig.
4b, Table 1). Tetramer-binding Gag-GW12-specific CD8+
Fig. 3. (a) Platelet counts (solid line) and plasma viral load (asterisks) in EIAV-infected horse A2164. The dotted line indicates the cutoff for thrombocytopenia
(100,000 platelets/Al). DPI, days post-EIAV inoculation. (b) Platelet counts and plasma viral load in EIAV-infected horse A2171. Annotations are the same as
for panel a.
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peak of 2.7% on DPI 99. In horse A2164, Gag-GW12-
specific CD8+ cell frequency remained between 0.0% and
0.08% until DPI 42, when 0.7% of nonstimulated peripheral
blood CD8+ cells bound the 7-6/Gag-GW12 tetramer. Gag-
GW12-specific CD8+ cell frequency reached a peak of 1.4%
(DPI 99) in A2164, and remained lower than in A2171 at all
time-points.
To confirm that the tetramers bound peptide-specific
CD8+ cells in both horses, PBMC from A2164 and A2171
were stimulated for 7 days with the Gag-GW12 and Env-
RW12 peptides. The 7-6/Env-RW12 tetramer did not bind
CD8+ cells in PBMC stimulated with the Gag-GW12
peptide, and the 7-6/Gag-GW12 tetramer did not bind
CD8+ cells in PBMC stimulated with the Env-RW12 peptide
(Fig. 5), confirming that both tetramers identified only
peptide-specific CD8+ cells.Env-RW12- and Gag-GW12-specific cytotoxic activity in
EIAV-infected horses A2171 and A2164
Env-RW12-specific cytotoxicity with specific lysis
greater than 10% over background (obtained using targets
not pulsed with peptide) was not detected in nonstimulated
PBMC at any time-point in either horse, indicating that the
tetramer was more sensitive than chromium-release assays
in detecting nonstimulated peripheral blood Env-RW12-
specific CD8+ cells. However, Env-RW12-specific cytoto-
xicity was detected in Env-RW12-stimulated PBMC from
both horses, and was higher in A2171 at all time-points
assayed (Table 1).
Gag-GW12-specific cytotoxicity with specific lysis
greater than 10% over background was not detected in
nonstimulated PBMC at any time-point in either horse, with
the exception of DPI 127 in A2171. As with Env-RW12, the
Table 1
Plasma viral load and Env-RW12- and Gag-GW12-specific CD8+ cell frequency and cytotoxicity in A2171 and A2164
DPIa A2171 A2164
Plasma
viral load
(RNA
copies/ml)
% Tetramer + CD8+ cells Cytotoxicityb Plasma
viral load
(RNA
copies/ml)
% Tetramer + CD8+ cells Cytotoxicityb
7-6/
Env-RW12
7-6/
Gag-GW12
Env-RW12 Gag-GW12 7-6/
Env-RW12
7-6/
Gag-GW12
Env-RW12 Gag-GW12
19 0 0.00 0.00 0.00 0.00 0 0.00 0.00 0.00 0.00
7 5754 0.00 0.00 2.77 0.00 29,190 0.00 0.03 1.60 0.11
14 24,150 0.68 0.36 25.21 5.87 362,460 0.15 0.01 0.00 0.00
19 4410 1.42 0.16 31.91 6.35 436,800 3.70 0.00 0.46 0.59
28 3121 2.38 0.09 38.77 27.94 37,086 1.93 0.00 38.19 9.17
35 23,100 3.94 0.84 40.49 34.98 394 4.61 0.08 28.75 18.49
42 773 4.62 2.19 50.64 43.20 149 5.86 0.73 44.26 36.13
57 40 3.41 1.15 29.14 16.18 3,649,800 1.84 0.29 12.64 1.60
71 3116 3.28 0.81 36.41 41.42 16,044 1.42 0.13 20.86 8.50
85 47 1.92 0.71 35.03 38.02 347,340 0.00 0.58 32.37 21.86
99 0 6.68 2.73 43.54 24.30 2041 2.96 1.35 42.28 11.10
127 0 3.00 1.23 52.66 63.35 250,320 0.80 0.44 20.61 35.77
a Days post-EIAV inoculation.
b % specific lysis of Env-RW12 or Gag-GW12 peptide-pulsed ELA-A1-matched equine kidney target cells using PBMC effectors stimulated for 7 days with
Env-RW12 or Gag-GW12 peptides.
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in detecting nonstimulated peripheral blood Gag-GW12-
specific CD8+ cells. On most days assayed after DPI 28,
Gag-GW12-specific cytotoxicity was detected in Gag-
GW12-stimulated PBMC from both horses, and was always
higher in A2171 (Table 1).
Sustained control of viral load correlated with
Gag-GW12-specific, but not Env-RW12-specific CD8+ cell
frequency, and was not associated with neutralizing
antibody activity
In A2171 (which controlled viral load and clinical
disease), viral load inversely correlated with Gag-GW12-
specific CD8+ cell frequency (P = 0.0308, r = 0.6489),
while no correlation was observed between viral load and
Env-RW12-specific CD8+ cell frequency. In horse A2164
(which did not control viral load or clinical disease), no
correlation was observed between viral load and Gag-GW12-
specific CD8+ cell frequency. Although viral load inversely
correlated with Env-RW12-specific CD8+ cell frequency
(P = 0.0216, r = 0.6789) in A2164, this immunodominant
Env-RW12-specific CD8+ response was not effective in
limiting viral replication. In both horses, neutralizing anti-
body was detected very early (DPI 14) in plasma, with90%
virus reduction by DPI 35 (Fig. 6). Although neutralizing
antibody activity was higher in A2171 than in A2164 for all
days assayed, the difference was not significant (Fig. 6).
Recognition of Env-RW12 and Gag-GW12 CTL epitope
plasma virus variants
To determine if CTL escape contributed to the
uncontrolled viral replication in A2164, segments of
plasma viral genes which included the coding regions forthe Env-RW12 and Gag-GW12 CTL epitopes were
cloned and sequenced. In DPI 7 plasma from both
horses, amino acid changes were not present within the
Env-RW12 epitope in the majority of clones (Figs. 7a,d).
However, amino acid changes were present within the
Env-RW12 epitope in DPI 21 plasma from both horses
(Fig. 7b,e). For A2171, the predominant DPI 21 Env-
RW12 variant peptide RVEDVTNTVEYW (11/20 clones;
Fig. 7b), designated Env-V9, was synthesized and used
to pulse target cells in a chromium-release assay.
Although Env-RW12-stimulated CTL effectors derived
from A2171 DPI 26 cryopreserved PBMC recognized
Env-V9, recognition was less efficient than that for Env-
RW12 (Fig. 8a). Env-V9-stimulated effectors displayed
similar recognition of Env-RW12 and Env-V9, indicating
that Env-V9 was not an escape variant. Although the
RVEDVTNTTEYW variant (designated Env-T9) was of
low frequency in A2171 DPI 21 plasma (5/20 clones), it
was actually recognized more efficiently by Env-RW12
and Env-T9-stimulated effectors than was the original
Env-RW12 epitope (Fig. 8b). For A2164, the DPI 21
cloned sequences revealed changes or deletions in
several different Env-RW12 amino acids, but the
RVEHVTNTAEYW (6/20 clones), designated Env-H4,
and the RVEDVMNTAEYW (6/20 clones), designated
Env-M6, were predominant (Fig. 7e). Using CTL
effectors derived from A2164 DPI 26 cryopreserved
PBMC, both Env-H4 and Env-M6 were recognized, but
less efficiently than Env-RW12 (Figs. 9a,b). By DPI 127,
100% of the cloned sequences from A2164 plasma
contained an RVEHVTNTTEYW variant sequence (Fig.
7c), designated Env-H4T9, that was not recognized by
DPI 127 cryopreserved CTL and was thus an escape
variant (Fig. 9c). In contrast to A2164, plasma viral
RNA was not detected in A2171 on DPI 127, indicating
Fig. 4. (a) Plasma viral load in A2164 (dotted line) and A2171 (solid line), and Env-RW12-specific CD8+ cell frequency (percentage of CD8+ nonstimulated
PBMC that were 7-6/Env-RW12 tetramer positive) in A2164 (white bars) and A2171 (gray bars). DPI, days post-EIAV inoculation. (b) Plasma viral load in
A2164 (dotted line) and A2171 (solid line), and Gag-GW12-specific CD8+ cell frequency (percentage of CD8+ nonstimulated PBMC that were 7-6/Gag-
GW12 tetramer positive) in A2164 (white bars) and A2171 (gray bars).
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78 (the last day viral RNA could be recovered from
A2171 plasma in sufficient quantities to clone and
sequence), the majority of clones (7/10) contained a 14
amino acid deletion that eliminated the first 5 residues of
Env-RW12 (Fig. 7f). This variant (designated Env-Del)
was recognized at a low level and only at the highest
peptide concentration by DPI 85 cryopreserved Env-
RW12-stimulated CTL, and was therefore considered an
escape variant (Fig. 8c).
Limited variation was observed within the Gag-GW12
epitope in cloned plasma viral sequences from both horses.
None of the DPI 7 clones from either horse had amino acid
changes within Gag-GW12 (Figs. 10a,c), nor did any of theclones from DPI 78 plasma from A2171 (Fig. 10d).
However, 6/8 clones had a GSQKLNTGNCNW variant
sequence in DPI 127 plasma from A2164 (Fig. 10b). This
variant, designated Gag-N6, was recognized less efficiently
than Gag-GW12 by A2164 DPI 127 cryopreserved CTL
(Fig. 9d).Discussion
This study describes the development and use of the
first tetramers that identify antigen-specific CD8+ cells in
the horse. The Gag-GW12- and Env-RW12-specific
CD8+ cell frequency and functional CTL activity were
Fig. 5. Representative anti-equine CD8 and tetramer staining for DPI 35 PBMC from A2171 (a–g) and A2164 (h–n). (a, h) Nonstimulated PBMC wit tetramer labeling. (b, i) Nonstimulated PBMC labeled
with the 7-6/Env-RW12 tetramer. (c, j) Nonstimulated PBMC labeled with the 7-6/Gag-GW12 tetramer. (d, k) Env-RW12-stimulated PBMC labeled wi e 7-6/Env-RW12 tetramer. (e, l) Env-RW12-stimulated
PBMC labeled with the 7-6/Gag-GW12 tetramer. (f, m) Gag-GW12-stimulated PBMC labeled with the 7-6/Gag-GW12 tetramer. (g, n) Gag-GW12-st lated PBMC labeled with the 7-6/Env-RW12 tetramer.
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Fig. 6. Neutralizing antibody activity in A2164 and A2171, determined by
incubating equal volumes of test plasma with EIAV stock virus followed by
titration in cell culture. % virus reduction was calculated by subtracting the
TCID50 obtained using test plasma from the TCID50 obtained using
negative control plasma, and dividing the result by the TCID50 obtained
using negative control plasma. The end result was multiplied by 100. Each
data point represents the mean of three separate assays. Error bars are 2 SD.
DPI, days post-EIAV inoculation. Plasma viral loads (viral RNA copies/ml)
for A2164 and A2171 on the days assayed for neutralizing antibody are
tabulated for reference.
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release assays during the initial 127 days post-EIAV
inoculation in two horses (A2171 and A2164) sharing the
ELA-A1 haplotype. In addition, neutralizing antibody
responses were evaluated using a virus reduction method.
Both horses developed an initial peak viremia 12–19
DPI, which both horses terminated. However, only horse
A2171 maintained efficient control of viral load. This
horse had more robust Gag-GW12- and Env-RW12-
specific CTL responses, and higher frequencies of Gag-
GW12- and Env-RW12-specific CD8+ cells than did
A2164. Interestingly, control of viral load by horse
A2171 correlated with Gag-GW12-specific, but not
Env-RW12-specific CD8+ cell frequency, despite the
dominance of the Env-RW12 response. This was likely
due to Env-RW12 escape viral variants, which were
identified in both horses. Although Gag-GW12 CTL
escape did not occur, a Gag-GW12 epitope variant arose
in A2164 that was recognized less efficiently than the
original epitope.
The 7-6/Env-RW12 and 7-6/Gag-GW12 tetramers
allowed efficient and early determination of antigen-specific
CD8+ cell frequency in EIAV-infected horses sharing the
ELA-A1 haplotype. Both tetramers bound CD8+ cells in a
peptide-specific, MHC class I-specific manner, and both
tetramers were more sensitive than chromium-release assays
in identifying antigen-specific, MHC class I-restricted
CD8+ cells in nonstimulated PBMC. The tetramers likely
identified functional CD8+ cells since chromium-release
assays confirmed CTL activity in the same population of
PBMC following peptide stimulation. Although reagents for
performing other CD8+ T lymphocyte functional assays in
the horse are available (Breathnach et al., 2005; Hines et al.,2003; Pedersen et al., 2002), chromium-release assays were
used because they provide results with direct functional
relevance that are comparable to those obtained by
ELISPOT or intracytoplasmic IFN-g staining (Michel et
al., 2002; Sun et al., 2003). Additionally, these other
functional assays have not yet been optimized for use in
the EIAV system. In general, the timing and magnitude of
the CTL responses as determined by the tetramers used in
this study were in agreement with those observed in SIV-
infected rhesus monkeys (Egan et al., 1999; Kuroda et al.,
1998).
The early neutralizing antibody responses in A2171 and
A2164 were unexpected. We have previously used virus
reduction assays to identify neutralizing antibody activity as
early as 45 DPI in an EIAVWSU5-infected Arabian horse
(Mealey et al., 2003). Other studies have reported EIAV-
specific neutralizing antibody as early as 38 DPI (Kono,
1969), 44 DPI (Salinovich et al., 1986), 52 DPI (Carpenter
et al., 1987), and between 2 and 3 months post-inoculation
(Hammond et al., 1997, 2000; Howe et al., 2002; Leroux et
al., 1997; O’Rourke et al., 1989). Differences in assay
sensitivity, virus strain, inoculation dose, and MHC class II
haplotypes might explain the discrepancies in these results.
Analysis of EIAV SU envelope sequences derived from
SCID and immunocompetent foals within 35 DPI indicates
that adaptive immune selection of SU variants occurs early
during infection (Mealey et al., 2004), and indirectly
corroborates the early appearance of neutralizing antibody
observed in the present study. Moreover, neutralizing
antibody can be detected as early as 14 DPI in SIV-infected
rhesus monkeys (Schmitz et al., 2003). Depletion of B
lymphocytes in these monkeys results in a delayed
neutralizing antibody response, but does not affect the rapid
decline of peak plasma viremia during the first 3 weeks of
infection. However, an inverse correlation exists between
neutralizing antibody titer and plasma virus level, suggest-
ing that neutralizing antibody contributes to the control of
SIV replication during the post-acute phase of infection
(Schmitz et al., 2003). In the present study, the similar levels
of neutralizing antibody in A2171 and A2164 suggested that
the observed differences in viral load and clinical disease
were due to differences in CTL-mediated control of EIAV
replication. However, qualitative differences in the early
neutralizing antibody responses may have contributed to the
differences in viral load and clinical disease observed in
A2171 and A2164.
Based on tetramer staining and CTL activity, the Env-
RW12 response was dominant over the Gag-GW12
response in both horses. However, epitope variants arose
in both horses that eventually escaped recognition by Env-
RW12 CTL. Nonetheless, the Env-RW12-specific CTL
response may have been important in the early control of
viral load, prior to the appearance of escape variants.
Although the immunodominant Env-RW12 response is
composed of high avidity CTL, Env-RW12 escape occurs
and is correlated with progressive disease (Mealey et al.,
Fig. 7. (a) Deduced amino acid sequences of EIAVWSU5 SU env clones (SU amino acids 182–238) obtained from A2164 DPI 7 plasma. The EIAVWSU5
consensus sequence (GenBank accession no. AF247394) is shown and the Env-RW12 CTL epitope is in bold and underlined. The number of clones with a
given sequence over the total number of sequenced clones is indicated in parentheses to the right of the clone name. (b) Deduced amino acid sequences of
EIAVWSU5 SU env clones obtained from A2164 DPI 21 plasma. Annotations are the same as for panel a. (c) Deduced amino acid sequences of EIAVWSU5 SU
env clones obtained from A2164 DPI 127 plasma. Annotations are the same as for panel a. (d) Deduced amino acid sequences of EIAVWSU5 SU env clones
obtained from A2171 DPI 7 plasma. Annotations are the same as for panel a. (e) Deduced amino acid sequences of EIAVWSU5 SU env clones obtained from
A2171 DPI 21 plasma. Annotations are the same as for panel a. (f) Deduced amino acid sequences of EIAVWSU5 SU env clones obtained from A2171 DPI 78
plasma. Annotations are the same as for panel a.
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variants following acute SIV infection in rhesus monkeys
(O’Connor et al., 2002). Given that the high avidity
immunodominant Env-RW12 CTL are directed against the
highly variable V3 region of EIAV SU, it is not surprising
that there was no correlation between viral load and Env-
RW12 frequency in A2171. Since the V3 region is a target
for neutralizing antibody (Ball et al., 1992), neutralizing
antibody selection pressure may have contributed to the
appearance of Env-RW12 epitope variants. The enhancedrecognition of the Env-T9 epitope variant in A2171 was
interesting, and was likely the reason this variant was
present in low numbers. The enhanced recognition could
have been due to higher affinity binding to the TCR, higher
affinity binding to MHC class I, or a combination of both.
Epitope variants that are recognized more efficiently than
the original CTL epitope have been previously observed in
an EIAV-infected horse (Mealey et al., 2003). Although an
inverse correlation existed between viral load and Env-
RW12 frequency in A2164, this correlation was not
Fig. 8. A2171 CTL recognition of ELA-A1-matched equine kidney (EK)
target cells pulsed with original or epitope variant peptides. Chromium-
release assays used EK targets pulsed with increasing concentrations of
each peptide (101 to 104 nM), and an effector:target ratio of 20:1. Effectors
were cryopreserved PBMC stimulated for 7 days with the original or the
variant epitope peptides. Specific lysis values are shown after subtraction of
background (specific lysis of targets not pulsed with peptide). (a) DPI 26
CTL recognition of the original epitope peptide Env-RW12 (RVEDVTN-
TAEYW) and the DPI 21 plasma virus epitope variant Env-V9
(RVEDVTNTVEYW). (b) DPI 26 CTL recognition of the original epitope
peptide Env-RW12 and the DPI 21 plasma virus epitope variant Env-T9
(RVEDVTNTTEYW). (c) DPI 85 CTL recognition of the original epitope
peptide Env-RW12 and the DPI 78 plasma virus epitope variant Env-Del
(KKVNLTNTAEYW).
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negative correlation was due to immune suppression
associated with uncontrolled viral replication in A2164,
especially since Env-RW12 CD8+ cell frequency was lower
in A2164 than in A2171 at most time-points assayed.
Immunosuppression is known to occur during febrile
episodes in EIAV-infected horses (Murakami et al., 1999;
Newman et al., 1991).
An inverse correlation between Gag-GW12 frequency
and viral load was observed in A2171 but not in A2164.
This suggested that Gag-GW12 CTL contributed to
control of viral replication and clinical disease in
A2171. The p15 region of Gag (which contains Gag-
GW12), is more highly conserved than the V3 region of
SU, which contains Env-RW12 (Chung et al., 2004;
Leroux et al., 1997; Mealey et al., 2003, 2004). In
addition, this region of Gag contains CTL epitope clusters
that are recognized by horses with disparate MHC class I
backgrounds (Chung et al., 2004), and is likely an
important target for protective CTL responses. Unlike
Env-RW12, Gag-GW12 variants did not occur in A2171.
However, an amino acid change within the epitope
resulted in less efficient CTL recognition in A2164. The
lower Gag-GW12 frequency combined with Gag-GW12
epitope variation could have contributed to the higher
viral load and progressive disease observed in A2164.
Further studies with additional horses are needed to
confirm these observations.
Although A2164 and A2171 shared the ELA-A1
haplotype, differences were observed in Env-RW12 and
Gag-GW12 CD8+ cell frequency and functional CTL
activity. These differences were likely due to MHC class
II disparity, resulting in recognition of different helper
epitopes and subsequent dissimilar CTL priming efficiency
and maintenance. The differences in neutralizing antibody
activity could have a similar explanation. Additionally, since
these horses were not ELA-A1 homozygotes, other MHC
class I alleles could have contributed to CTL responses that
were not measured. It is therefore possible that CTL other
than Env-RW12 and Gag-GW12 were involved in the more
efficient control of viral load and clinical disease observed
in A2171.
The results obtained in this study suggest that neutral-
izing antibody and CTL directed against variable EIAV
envelope epitopes are important in the control of initial
viremia, but are not sufficient for sustained control due to
viral escape. Although the Gag-GW12 CTL response was
subdominant to the Env-RW12 CTL response in the horses
of this study, Gag-GW12 epitope escape did not occur in
A2171, and this response correlated with sustained control
of plasma viremia and clinical disease in A2171. Further
work with tetramers could verify these observations. These
data should be useful in designing protective vaccines
against EIAV in horses, and may have similar implications
for designing protective vaccines against other lentiviruses.
In addition, MHC class I/peptide tetramers proved useful
Fig. 9. A2164 CTL recognition of ELA-A1-matched equine kidney (EK) target cells pulsed with original or epitope variant peptides. Chromium-release assays
used EK targets pulsed with increasing concentrations of each peptide (101 to 104 nM), and an effector:target ratio of 20:1. Effectors were cryopreserved
PBMC stimulated for 7 days with the original or the variant epitope peptides. Specific lysis values are shown after subtraction of background (specific lysis of
targets not pulsed with peptide). (a) DPI 26 CTL recognition of the original epitope peptide Env-RW12 and the DPI 21 plasma virus epitope variant Env-H4
(RVEHVTNTAEYW). (b) DPI 26 CTL recognition of the original epitope peptide Env-RW12 and the DPI 21 plasma virus epitope variant Env-M6
(RVEDVMNTAEYW). (c) DPI 127 CTL recognition of the original epitope peptide Env-RW12 and the DPI 127 plasma virus epitope variant Env-H4T9
(RVEHVTNTTEYW). (d) DPI 127 CTL recognition of the original epitope peptide Gag-GW12 (GSQKLTTGNCNW) and the DPI 127 plasma virus epitope
variant Gag-N6 (GSQKLNTGNCNW).
R.H. Mealey et al. / Virology 339 (2005) 110–126 121for identifying and quantifying early antigen-specific
CD8+ cell responses in the horse, and the development
of additional tetramers will enable a more complete
analysis of EIAV-specific CTL responses in additional
horses.Materials and methods
Horses
Two Arabian 2-year-old horses, A2164 and A2171, were
inoculated intravenously with 107 50% tissue culture
infective doses (TCID50) of the WSU5 strain of EIAV
(O’Rourke et al., 1989). The equine leukocyte alloantigen
(ELA)-A types were determined serologically (Bailey, 1980)with reagents kindly provided by Dr. Ernest Bailey (Uni-
versity of Kentucky), and were A1/w11 for A2164, and A1/
A4 for A2171. Rectal temperature and clinical status were
recorded daily, and for the first 7 weeks post-infection,
platelet counts were performed on whole blood collected
every 2 days, then twice weekly thereafter. Clinical disease
episodes were defined when thrombocytopenia (platelet
count < 100,000/Al), with or without fever (rectal temper-
ature > 101.5 -F), occurred on at least 2 consecutive
collection days. For determination of viral load, plasma
was collected and stored at 80 -C every 2 days for the first
7 weeks post-infection, then twice weekly thereafter. Hepari-
nized whole blood was collected weekly for isolation of
PBMC by density gradient centrifugation using Histopaque-
1077 (Sigma-Aldrich). Each time PBMC were isolated,
aliquots were suspended in fetal bovine serum (FBS) with
Fig. 10. (a) Deduced amino acid sequences of EIAVWSU5 gag clones (Gag amino acids 1–57) obtained from A2164 DPI 7 plasma. The EIAVWSU5 consensus
sequence (GenBank accession no. AF247394) is shown and the Gag-GW12 CTL epitope is in bold and underlined. Other annotations are the same as for Fig.
7a. (b) Deduced amino acid sequences of EIAVWSU5 gag clones obtained from A2164 DPI 127 plasma. Annotations are the same as for panel a. (c) Deduced
amino acid sequences of EIAVWSU5 gag clones obtained from A2171 DPI 7 plasma. Annotations are the same as for panel a. (d) Deduced amino acid sequences
of EIAVWSU5 gag clones obtained from A2171 DPI 78 plasma. Annotations are the same as for panel a.
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involving horses were approved by the Washington State
University Institutional Animal Care and Use Committee.
Tetramer construction
Identification of the two ELA-A1-restricted EIAV-
specific CTL epitopes Env-RW12 and Gag-GW12, as well
as cloning and identification of the ELA-A1-associated
MHC class I gene 7-6, which encodes the class I molecule
that presents Env-RW12 and Gag-GW12, are described
elsewhere (McGuire et al., 2003; Mealey et al., 2003).
Tetramers were constructed using published methods
(Altman et al., 1996). Specifically, the extracellular
regions of 7-6 cDNA were PCR amplified using a
forward primer located in exon 2, incorporating a HindIII
restriction site, a ribosomal binding site, a transcriptional
spacer element and a start codon, together with a reverse
primer spanning exons 4 and 5, incorporating a BamHI
site. The amplified product was cloned into the pGEM-4Z
vector (Promega) modified to contain a biotinylation site,
a GS linker and a T7 terminator sequence. Horse h2m
cDNA (Ellis and Martin, 1993) was similarly amplified
and cloned into the pGEM-4Z vector modified to contain
a T7 terminator sequence. E. coli BL21(DE3) pLysS were
transformed with these plasmids, and high-expressing
colonies were selected following screening with SDS-
PAGE. Suitable clones were grown and induced to over-
express protein by addition of IPTG to the growth media.
Inclusion bodies were extracted and purified by mechan-
ical disruption of the cells. The 7-6 heavy chain wasrefolded with horse h2m and each of the two peptides
(Env-RW12 and Gag-GW12), was concentrated and
biotinylated. Purification of the biotinylated monomer
was achieved by FPLC (using size exclusion followed by
ion exchange), which resulted in a final yield of 0.5–2 mg.
Tetramers were generated as required by adding streptavidin
conjugated to phycoerythrin (BD Pharmingen) to each
monomer over the course of 15 h to a final molar ratio of
1:4. The resulting tetramers were designated 7-6/Env-RW12
and 7-6/Gag-GW12.
Cytotoxicity assays
Chromium-release assays (McGuire et al., 1994; Mealey
et al., 2003) were performed weekly using both freshly
isolated and peptide-stimulated PBMC effectors. To
prepare peptide-stimulated PBMC, Env-RW12 or Gag-
GW12 peptides (final concentration 10 AM) were incu-
bated with freshly isolated PBMC for 2 h at 37 -C with
occasional mixing before centrifugation at 250  g for 10
min. PBMC were then resuspended at 2  106/ml in RPMI
1640 medium with 10% FBS, 20 mM HEPES, 10 Ag/ml
gentamicin, and 10 AM 2-mercaptoethanol. Flat-bottomed
24-well tissue culture plates were seeded with 1 ml/well,
and incubated at 37 -C with 5% CO2 for 7 days at 37 -C.
When cryopreserved PBMC were used to assess CTL
recognition of epitope variant peptides, stimulations were
performed as above except that the Env-RW12 and Gag-
GW12 stimulating peptides were used at 40 AM, and 10 U/ml
recombinant human IL-2 plus irradiated autologous PBMC
stimulators were added. ELA-A1-matched equine kidney
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RW12 or Gag-GW12 peptides at 105 nM for 2 h at 37 -C in
96-well plates containing 50 Al/well DMEM with 5% calf
serum and 25 ACi 51Cr/ml. To compare CTL recognition of
epitope variants, EK targets were pulsed with increasing
concentrations of peptides (10 1 to 104 nM). After washing
the plates, the PBMC effectors (either freshly isolated or
peptide-stimulated) were added at an effector:target cell
ratio of 20:1, incubated for 17 h, and 100 Al supernatant
removed to determine 51Cr release. The formula percent
specific lysis = [(E  S)/(M  S)]  100 where E = the
mean of 3 test wells, S = the mean spontaneous release from
3 target cell wells without effector cells, and M = the mean
maximal release from 3 target cell wells with 2% Triton X-
100. Values for specific lysis were reported after subtracting
the background-specific lysis (obtained using targets not
pulsed with peptide). The formula used to calculate standard
error of the percent specific lysis accounts for the variability
of E, S, and M (McGuire et al., 1994; Siliciano et al., 1985).
Specific lysis >10% over background was considered
significant.
Flow cytometric analysis of Env- and Gag-specific CD8+
cells
The murine anti-equine CD8 monoclonal antibody
HT14A (Kydd et al., 1994) directly conjugated to FITC
(HT14A-FITC), and the PE-labeled 7-6/Env-RW12 and 7-
6/Gag-GW12 tetramers were used for staining. Freshly
isolated or peptide-stimulated PBMC were suspended in
wash buffer consisting of phosphate-buffered saline with
2% GG-free horse serum, 10% ACD, 10 mM EDTA, and
0.2% NaN3. Cells (10
6 PBMC in 50 Al wash buffer) were
stained first with 50 Al PE-conjugated 7-6/Env-RW12 or 7-
6/Gag-GW12 tetramer at the determined optimal concen-
tration (Fig. 1) for 30 min at 37 -C, washed, then 50 Al (1
Ag) HT14A-FITC was added for 15 min at 4 -C. The cells
were washed again and two-color analysis was performed
on gated lymphocytes using a FACSort flow cytometer
(Becton Dickinson), with Cell Quest and Paint-A-Gate Pro
software.
Plasma neutralizing antibody activity
Neutralizing antibody activity in frozen heparinized
plasma was determined using a virus reduction method
(Mealey et al., 2001, 2003). Briefly, 300 Al heparinized
plasma was heat inactivated then mixed with 300 Al
EIAVWSU5 stock (10
4 TCID50/ml), and incubated for 1 h at
37 -C. The same was performed using negative control
plasma from four horses not infected with EIAV. The negative
controls included pre-inoculation plasma from A2164 and
A2171. For each plasma–virus mixture, 3-fold serial
dilutions were made, and titration performed in EK cell
culture (O’Rourke et al., 1988). Three separate assays were
performed for each day assayed, and each assay was done induplicate. Percent virus reduction was calculated using the
formula:
% virus reduction ¼ mean negative control plasma titer  test plasma titer
mean negative control plasma titer
 100
The results obtained from three separate assays were
used to report a mean virus reduction for each day assayed.
Viral RNA purification
Viral RNA was isolated from 140 Al frozen EDTA
plasma using a QIAamp Viral RNA kit (Qiagen) (Mealey et
al., 2003), DNAse I-treated on the spin column (DNAse 1
set, Qiagen), eluted in 60 Al nuclease-free water, and frozen
at 20 -C.
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR (Mealey et al., 2003) was
used with modifications to determine plasma viral load by
amplification of a 167-bp segment (nt 1637–1803) of the
EIAVWSU5 (GenBank accession no. AF247394) gag gene.
Standard RNA template was made by transcribing a cloned
1445-bp gag fragment spanning nucleotides 475–1920
EIAVWSU5 using a Ribomax T7 polymerase transcription
kit (Promega). Standard RNA template copy numbers were
determined by optical density and dilutions made in
nuclease-free water containing 30 Ag/ml tRNA and 40 U/
ml Rnasin. Primers 1637F (5V AGCCAGGACATTTATC-
TAGTCAATGTAGAGCA CC 3V) and 1803R (5V GTGCT-
GACTCTTCTGTTGTATCGGGAAAGTTTG 3V), along
with a previously reported gag-specific probe (Cook et al.,
2002) were used in duplicate 25 Al reactions utilizing an
iScript One-Step RT-PCR kit for probes (BioRad), 200 nM
of each primer and probe, 40 U Rnasin, and 10 Al plasma
RNA template. Reactions were done in an iCyler with the
iQ Real-Time PCR Detection System and software
(BioRad) under the following conditions: 30 min at
50 -C, 3.5 min at 95 -C, 50 cycles at 95 -C for 15 s
and 60 -C for 1 min. Sensitivity was determined using a
dilution series of the standard RNA transcripts. The dilu-
tion containing 1 RNA copy was positive in 40% (4/10) of
the replicates, while the dilutions containing 10 RNA
copies or more were positive in 100% (10/10) of the
replicates. The reliable detection limit, therefore, was
somewhere between 43 and 428 RNA copies/ml when 140
Al plasma for the RNA extraction and 10 Al of the 60 Al eluate
were used.
RT-PCR amplification of plasma EIAV genome regions
containing CTL epitopes
RT-PCRwas performed using a SuperScript One-Step RT-
PCR kit (Life Technologies), with 5 Al template RNA eluate
in 50 Al total reaction volume as described (Mealey et al.,
R.H. Mealey et al. / Virology 339 (2005) 110–1261242003). Briefly, Env-RW12 is contained within EIAVWSU5 nt
5868–6164 and the following primers and reaction con-
ditions were used: forward primer (5616F), 5V-CAACATT-
ATATAGGGTTGGTAGC-3V; reverse primer (6164R), 5V-
AGCAATCCCTTTCTCCTGT-3V; 30 min at 45 -C, 2 min at
94 -C, followed by 40 cycles of 30 s at 94 -C, 30 s at 59 -C,
1 min at 72 -C, and then 7 min at 72 -C. Gag-GW12 is
contained within EIAVWSU5 nt 406–694 and the following
primers and reaction conditions were used: forward primer
(406F), 5V-GACAGCAGAGGAGAACTTAC-3V; reverse
primer (694R), 5V-CCTCTCTTTCTTGTCCTG-3V; 30 min
at 45 -C, 2 min at 94 -C, followed by 40 cycles of 30 s at
94 -C, 30 s at 54 -C, 30 s at 72 -C, and then 7 min at 72 -C.
Cloning and sequencing of RT-PCR products
Amplified products from multiple RT-PCR reactions
were purified from agarose gels using a QIAquick Gel
Purification Kit (Qiagen Inc.) and cloned into the pCR2.1-
TOPO TA cloning vector (Invitrogen) as described (Mealey
et al., 2003, 2004). Nucleotide sequences were determined
by the Laboratory for Biotechnology and Bioanalysis
(Washington State University, Pullman, WA), using an
ABI Prism 377 (Applied Biosystems) automated DNA
sequencer, and were then submitted to GenBank (accession
numbers AY958280 –AY958308, and AY968055 –
AY968061). Deduced aa sequences were compared to the
EIAVWSU5 consensus sequence using ClustalW and Box-
shade programs.
Statistical analysis
To determine correlations between viral load and
tetramer-positive CD8+ cell frequency, linear regression
(Motulsky, 1995) was performed using GraphPad InStat
version 3.06 (GraphPad Software, San Diego, CA).Acknowledgments
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